

Article

In Vitro Astroglial Dysfunction Induced by Neurotoxins: Mimicking Astrocytic Metabolic Alterations of Alzheimer's Disease

Jéssica Taday , Fernanda Telles Fróes, Marina Seady, Carlos Alberto Gonçalves *  and Marina Concli Leite 

Departamento de Bioquímica, Instituto de Ciências Básicas da Saúde, Universidade Federal do Rio Grande do Sul (UFRGS), Porto Alegre 90035-003, Brazil; jessica.taday@ufrgs.br (J.T.); fernanda.froes@ufrgs.br (F.T.F.); pedraseady.marina@mayo.edu (M.S.); marina.leite@ufrgs.br (M.C.L.)

* Correspondence: casg@ufrgs.br

Abstract: Astrocytes play fundamental roles in the maintenance of brain homeostasis. The dysfunction of these cells is widely associated with brain disorders, which are often characterized by variations in the astrocyte protein markers GFAP and S100B, in addition to alterations in some of its metabolic functions. To understand the role of astrocytes in neurodegeneration mechanisms, we induced some of these metabolic alterations, such as energy metabolism, using methylglyoxal (MG) or fluorocitrate (FC); and neuroinflammation, using lipopolysaccharide (LPS) and streptozotocin (STZ), which is used for inducing Alzheimer's disease (AD) in animal models. We showed that MG, LPS, STZ and FC similarly caused astrocyte dysfunction by increasing GFAP and reducing S100B secretion. In the context of AD, STZ caused an amyloid metabolism impairment verified by increases in A β 1-40 peptide content and decreases in the amyloid degradation enzymes, IDE and NEP. Our data contribute to the understanding of the role of astrocytes in brain injury mechanisms and suggest that STZ is suitable for use in vitro models for studying the role of astrocytes in AD.

Keywords: astrocytes; Alzheimer's disease; streptozotocin; lipopolysaccharide; fluorocitrate; methylglyoxal



Citation: Taday, J.; Fróes, F.T.; Seady, M.; Gonçalves, C.A.; Leite, M.C. In Vitro Astroglial Dysfunction Induced by Neurotoxins: Mimicking Astrocytic Metabolic Alterations of Alzheimer's Disease. *Metabolites* **2024**, *14*, 151. <https://doi.org/10.3390/metabo14030151>

Academic Editors: Marta Tomczyk and Magdalena Podlacha

Received: 1 February 2024

Revised: 21 February 2024

Accepted: 27 February 2024

Published: 1 March 2024



Copyright: © 2024 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (<https://creativecommons.org/licenses/by/4.0/>).

1. Introduction

Astrocytes are implicated in most of the studies of brain disorders accompanied by cognitive impairment, mostly associated with neurodegenerative diseases. Some mechanisms of cognitive impairment are related to astrocytic dysfunction [1–3]. Aging, the main risk factor in neurodegenerative diseases [4,5], changes brain metabolism, and studies suggest that cognitive decline can be affected by astroglial metabolism dysfunction [6]. In this sense, considering the accelerated aging of the global population, it is crucial to better understand the role of astrocytes in the neurodegeneration processes.

Astrocytes are glial cells involved in maintaining brain homeostasis and developing synapses and plasticity, contributing to memory consolidation [3,7]. In this sense, it is important to highlight some of their characteristic proteins. S100B is a calcium-binding protein with toxic or trophic functions depending on the context and is considered a marker of brain damage [8]. Glial fibrillary acidic protein (GFAP) is a cytoskeletal protein which is usually associated with the activation of astrocytes [9]. Furthermore, astrocytes play a crucial role in cerebral glutamate metabolism by participating in the glutamate–glutamine cycle, which is related to the cognition process. These cells uptake glutamate from the synaptic cleft and then convert it to glutamine by glutamine synthetase (GS) or use this glutamate to synthesize the endogenous antioxidant glutathione (GSH) [7,10,11]. The disruption of some of these astrocyte functions is associated with the early stages of brain disorders [2,3,12].

Brain degenerative diseases are associated with numerous factors, such as cellular energy metabolism impairment, inflammatory responses and protein aggregation [13]. Many compounds have been used to mimic some of the alterations associated with the initiation or progression of neurodegeneration.

The inhibition of astrocytes by the administration of fluorocitrate (FC), which impairs energy metabolism by the inhibition of aconitase's impact on the citric acid cycle, specifically in astrocytes [14], has been linked to the inhibition of reactive astrocytes [15,16]. FC administration ameliorated cognitive impairment in models of traumatic brain injury [17] and ischemic stroke [15], highlighting the importance of astrocytes in cognitive damage progression. FC enters the astrocyte via monocarboxylate transporter 1 (MCT1); this lactate transporter is also essential for the brain's energy metabolism and is crucial for cognition [18].

Diabetes mellitus (DM), which leads to cognitive impairment, is a risk factor for neurodegenerative diseases [19]. Methylglyoxal (MG) is a reactive dicarbonyl metabolite of glucose, which is produced during DM and is also used to mimic its features in vitro [20–23] and in vivo [24,25]. MG leads to an increase in advanced glycation end products (AGEs), which can interact with and alter the levels and activity of their receptor (RAGE) in the brain. [26]. It should be emphasized that astrocytes express RAGE, which, in addition to AGEs [27], binds S100B [28,29] and amyloid beta ($A\beta$) peptide [30,31].

Furthermore, most neurodegenerative diseases and other cognitive impairment conditions are accompanied by neuroinflammation [32]. Lipopolysaccharide (LPS) is a bacterial toxin widely used to induce an inflammatory response by binding to the TLR4 receptor, expressed by glial cells, including astrocytes [33]. In fact, intracerebroventricular injection of LPS causes memory impairment in rats [34]. The TLR4 and RAGE receptors are reportedly altered in neurodegenerative diseases [35,36].

Cognitive impairment and memory loss are the main symptoms of Alzheimer's disease (AD), the most prevalent neurodegenerative disease, and are frequently related to the presence of characteristic cerebral alterations. Senile plates formed by amyloid beta ($A\beta$) peptide accumulation and neurofibrillary tangles (NFTs) formed by the hyperphosphorylation of tau protein [37] are considered hallmarks of the disease. However, AD is a multifactorial disease, and other biochemical alterations can start years before the appearance of its symptoms and hallmarks [38]. It is important to note that astrocytic alterations are found in the initial stages of Alzheimer's disease [12].

Various animal models are available to study AD characteristics, such as intracerebroventricular streptozotocin administration (ICV-STZ). ICV-STZ is a chemical-induced model of sporadic Alzheimer's disease that has been extensively explored [39–41], but the use of STZ in in vitro models has been little explored, especially in astrocytes [42]. The mechanism by which STZ induces AD is not entirely understood, but it is known that the compound can enter CNS cells via glucose transporter 2 (GLUT2) and interfere with the insulin receptor (IR), compromising the glycogen synthase kinase 3 (GSK3) pathway and affecting the metabolism of $A\beta$ peptide and tau phosphorylation. However, the capacity of this compound to interact with astroglial cells needs further investigation [43,44]. Having an appropriate model to study the role of astrocytes in AD is interesting because, even though the production of $A\beta$ by astrocytes is lower than that of neuronal production, considering their high number in the CNS, astrocytic $A\beta$ production is also significant [12]. In addition, astrocytes play an important role in $A\beta$ metabolism by sending it to the peripheral tissues or degrading it by enzymatic mechanisms such as via neprilysin (NEP) or insulin-degrading enzyme (IDE). Therefore, astrocytes can play a dual role in AD; they are protective in the early stages and prevent the accumulation of $A\beta$ peptides; however, upon the progression of the disease, they contribute to the production and accumulation of this peptide [45–47].

Astrocytes play a direct role in the protection from and development of neurodegenerative diseases and can be a key point for understanding neurodegenerative disease development, especially AD. However, it is not clear if astrocytic dysfunction induced by

different stimuli leads to metabolic alterations observed in AD. Therefore, the objective of the present study was to induce some Alzheimer's disease-associated dysfunctions in astrocytes by exposing primary astrocyte cultures to MG, FC, LPS or STZ to evaluate the astrocytes' function and A β metabolism. Our results showed that MG, FC, LPS and STZ caused astrocyte dysfunction and suggested that STZ is suitable for use in *in vitro* models for study of the role of astrocytes in some of the metabolic changes involved with AD.

2. Materials and Methods

2.1. Materials

Methylglyoxal (M0252), fluorocitric acid barium salt (F9634), lipopolysaccharides from *Escherichia coli* 055:B5 (L4005), streptozotocin (S0130), poly-L-lysine (P1274), methyl thiazolyl diphenyl-tetrazolium bromide (MTT) (M2128), neutral red (N4638), propidium iodide (P4170), bisbenzimidazole H 33258 (14530), amphotericin B solubilized (A9528), HEPES (H7006), sodium bicarbonate (NaHCO₃) (S5761), glucose (G5400), albumin from chicken egg white (A5253), phenylmethylsulfonyl fluoride (P7626), ethylene glycol-bis(β -aminoethyl ether)-N,N,N',N'-tetracetic acid (E4378), dimethyl sulfoxide (D8418), L-glutamic acid γ -monohydroxamate (G2253), anti-S100B antibody (SH-B1) (S2532), S100B protein from bovine brain (S6677), imidazole (I2399), *o*-phenylenediamine (P9029), reduced glutathione (G4251), phthaldialdehyde (P1378) and L-glutamate (G5889) were purchased from Sigma (St. Louis, MI, USA). Fetal calf serum (FCS) (12657-029), Dulbecco's modified Eagle's medium (DMEM) (31600-034), Dulbecco's phosphate-buffered saline (DPBS) (21600-010) and gentamicin (15710072) were purchased from Gibco (Carlsbad, CA, USA). Cell culture plates were purchased from Falcon (353047 for 24-well, 353043 for 12-well and 353072 for 96-well). Human GFAP (345996) was obtained from Calbiochem. Bovine serum albumin Cohn fraction V (1870) was purchased from Inlab (São Paulo, Brazil). L-[2,3-³H] Glutamate (ART0103) was purchased from Amersham International (Buckinghamshire, United Kingdom). Anti-nephrilysin (AB5458) and anti-IDE (AB9210) antibodies were obtained from Merck Millipore Corporation (São Paulo, Brazil). Anti-A β ₁₋₄₀ (sc-9129) antibody was obtained from Santa Cruz Biotechnology (Santa Cruz, CA, USA). Polyclonal anti-S100B (Z0311) and anti-GFAP (Z0334) antibodies were purchased from DAKO (São Paulo, Brazil) and anti-rabbit peroxidase (NA934V) and ECL Western blotting detection reagents (RPN3004) were purchased from GE (Little Chalfont, United Kingdom). Rhodamine phalloidin (R415) and acrylamide (15512-023) were purchased from Invitrogen (Waltham, MA, USA). The LDH activity kit (K014-2) was purchased from Bioclin (Belo Horizonte, Brazil). High-binding flat-bottomed plates (655081) used in enzyme-linked immunosorbent assays (ELISAs) were purchased from Greiner Bio-One (Frickenhausen, Germany). All other chemicals were purchased from local commercial suppliers.

2.2. Cell Culture

Procedures were carried out in accordance with the National Institutes of Health Guide for the Care and Use of Laboratory Animals and were approved by the Ethics Committee on the Use of Animals of the Federal University of Rio Grande do Sul (number 34855). Primary astrocyte cultures from Wistar rats were prepared as previously described [48]. Briefly, the cerebral cortices of newborn Wistar rats (1–4 days old) were removed and mechanically dissociated in Ca²⁺- and Mg²⁺-free Dulbecco's phosphate-buffered saline (DPBS), pH 7.4, containing (in mM): 137 NaCl; 2.66 KCl; 8.1 Na₂HPO₄; 1.47 KH₂PO₄ and 5.55 glucose. After centrifugation at 300 \times g for 5 min, the pellet was suspended in DMEM (pH 7.6) supplemented with 7.68 mM HEPES, 108.79 mM NaHCO₃, 50 mg/L amphotericin B, 2.5 mg/L gentamicin and 10% fetal calf serum (FCS). Cells were seeded in 12-, 24-, or 96-well plates (800,000, 300,000 and 50,000 cells/well, respectively) pre-coated with poly-L-lysine. Cultures were maintained in DMEM containing 10% FCS in 5% CO₂/95% air at 37 °C and the medium was changed every 3–4 days. Cells were allowed to grow to confluence and used at 21 days *in vitro*. We were unable to label neurons or microglia, using anti-NeuN or anti-Iba-1, respectively.

2.3. Experimental Design

The culture medium was replaced by DMEM without FCS (to avoid methodological interference from FCS) in the absence or presence of MG (from 5 to 500 μM), FC (from 1 to 100 μM), LPS (from 0.1 to 10 $\mu\text{g/mL}$), or STZ (from 2.5 to 250 μM), diluted in DPBS, which were used as the vehicles. The concentration range for each compound was chosen based on previous studies [23,49–51]. After 24 h of incubation, the extracellular medium was collected and cell scraping was used to collect the cells, as detailed in each methodological description. A schematic representation of the experimental procedure is shown in Figure 1.




Figure 1. Schematic representation of the experimental plan. Wistar rat astrocytes, cultured after reaching confluence, were exposed to MG (5; 50 or 500 μM), FC (1; 10 or 100 μM), LPS (0.1; 1 or 10 $\mu\text{g/mL}$), or STZ (2.5; 25 or 250 μM) for 24 h. After incubation, culture medium or intracellular lysate samples were collected for experimental analysis.

2.4. Methyl Thiazolyl Diphenyl-Tetrazolium Bromide Assay

Cells were incubated with 0.5 mg/mL methyl thiazolyl diphenyl-tetrazolium bromide (MTT) during the last 30 min of the incubation. The medium was removed and the MTT formazan crystals formed by MTT reduction were dissolved in DMSO. Absorbance values were measured at 560 and 650 nm using Spetramax I3 equipment, and MTT reduction was calculated using the following formula: [(abs 560 nm)–(abs 650 nm)]. Results were expressed as a percentage of control.

2.5. Neutral Red Incorporation Assay

Cells were treated with 50 $\mu\text{g/mL}$ neutral red (NR) for the last 30 min of the incubation. The medium was removed, and the cells were rinsed twice with phosphate-buffered saline (PBS: 50 mM NaCl, 20 mM NaH_2PO_4 and 80 mM Na_2HPO_4 , pH 7.4) for 5 min each time. NR dye taken up by viable cells was extracted with acetic acid/ethanol/water (1/50/49, v/v). Absorbance values were measured at 560 nm using the Spetramax I3 equipment, and results were expressed as a percentage of control.

2.6. Propidium Iodide Uptake Assay

Cells were treated with 7.5 μM propidium iodide (PI) for the last 15 min of incubation. Fluorescence was measured using 625 nm (excitation) and 713 nm (emission) in Spetramax I3 equipment. Results were expressed as a percentage of control.

2.7. Assessment of Lactate Dehydrogenase Activity

The extracellular enzymatic activity of lactate dehydrogenase (LDH) was measured with a commercial assay from Bioclin (Belo Horizonte, Brazil). Briefly, 50 μL of the extracellular medium was transferred to a 96-well plate. The substrate solution containing pyruvate and a solution containing NADH were added to the sample. The catalytic concentration was determined by the speed of decomposition of NADH, measured by the drop in absorbance at 340 nm during 4 min of testing using the Spetramax I3 equipment. Results were expressed as a percentage of control.

2.8. Cytochemistry for Actin and Nuclei

The cells were fixed with 4% paraformaldehyde in PBS for 20 min, rinsed with PBS and permeabilized with 0.1% Triton X-100 in PBS (same composition as used in 2.5), for 10 min at room temperature. Afterward, to stain actin, the cells were incubated for 20 min with 2.5 U/mL rhodamine phalloidin, washed with 0.2% Triton X-100 in PBS, and then, nuclei were stained by 100 μ M bisbenzimidazole for 10 min. Cells were visualized using an Olympus CKX41 Inverted Fluorescence Microscope, and representative images were captured.

2.9. S100B Measurement

The medium was collected (for S100B secretion) and the cells were scraped and homogenized in PBS (same composition as used in 2.5), containing 1 mM PMSF (phenylmethylsulfonyl fluoride) and 1 mM EGTA (ethylene glycol-bis (β -aminoethyl ether)-N,N,N',N'-tetracetic acid) with a syringe and needle (0.3 mm). S100B was measured by ELISA, as previously described [52]. Briefly, 50 μ L of the sample or standard (diluted in 0.2% albumin from chicken egg in PBS) plus 50 μ L of 50 mM tris buffer were incubated for 2 h at 37 °C on a microtiter plate previously coated overnight with monoclonal anti-S100B (diluted in carbonate buffer) at 4 °C and blocked for 1 h with 2% albumin from chicken egg in PBS at room temperature. Polyclonal anti-S100 (diluted in 0.5% albumin from chicken egg in PBS) was incubated for 30 min at 37 °C, and then, peroxidase-conjugated anti-rabbit antibody (diluted in 0.5% albumin from chicken egg in PBS) was added for 30 min at 37 °C. After incubating o-phenylenediamine for 30 min in the dark at room temperature, the colorimetric reaction was stopped with 3 M HCl and measured at 492 nm, using Spetramax I3 equipment. Data were compared with those of a standard curve (from 0.002 to 1 ng/mL) and intracellular S100B was normalized by the total protein content. Results are expressed as a percentage of control.

2.10. Glial Fibrillary Acidic Protein Measurement

The medium was removed, and the cells were scraped and homogenized in PBS containing 1 mM PMSF and 1 mM EGTA with a syringe and needle (0.3 mm). GFAP was measured by ELISA, as previously described [53]. Briefly, 50 μ L of standard or cell homogenate sample (diluted in 1 ng/ μ L bovine serum albumin) was incubated in a microtiter plate overnight at 4 °C and blocked for 2 h with 5% fat-free milk powder tris buffer solution (0.03 M 20 mM tris-HCl, pH 7.5, 0.5 M 137 mM NaCl) (M-TBS). Polyclonal anti-GFAP was incubated for 1 h at room temperature and then peroxidase-conjugated anti-rabbit antibody was added for 1 h at room temperature. After incubating with o-phenylenediamine for 30 min in the dark at room temperature, the colorimetric reaction was stopped with 3 M HCl and measured at 492 nm using the Spetramax I3 equipment. Data were compared with those of a standard curve (from 0.1 to 5 ng/mL) and normalized by the total protein content. Results were expressed as a percentage of control.

2.11. Glutamate Uptake Assay

Glutamate uptake was measured, as previously described by [54] with some modifications [55]. Briefly, cell cultures were incubated at 37 °C in Hank's balanced salt solution (HBSS), containing (in mM) 137 NaCl, 5.36 KCl, 1.26 CaCl₂, 0.41 MgSO₄, 0.49 MgCl₂, 0.63 Na₂HPO₄·7 H₂O, 0.44 KH₂PO₄, 4.17 NaHCO₃ and 5.6 glucose, pH 7.2. The assay was started by adding 0.1 mM L-glutamate and 0.05 μ Ci/mL L-[2,3-³H] glutamate. Incubation was stopped after 7 min by removing the medium and rinsing the cells three times with ice-cold HBSS. The cells were then lysed in a 0.5 M NaOH solution. Sodium-independent uptake was determined using N-methyl-D-glucamine instead of NaCl in the HBSS. Sodium-dependent glutamate uptake was obtained by subtracting the non-specific uptake from the total uptake to obtain the specific uptake. Radioactivity was measured in a PerkinElmer Tri-Carb 2300TR scintillation counter. Results were calculated and normalized by the total protein content and are expressed as a percentage of the control.

2.12. Reduced Glutathione Content Assay

The medium was removed, and the cells were scraped and homogenized in KCl phosphate buffer (140 mM, 20 mM, pH 7.4) using a syringe and needle (0.3 mm). Reduced glutathione (GSH) content was measured as previously described by [56]. Briefly, cell homogenates or standard GSH solution (0.977–500 μ M) were diluted in sodium phosphate buffer (0.1 M, pH 8.0) containing 5 mM EDTA, and proteins were precipitated with 1.7% meta-phosphoric acid. The supernatant was incubated with o-phthaldialdehyde (1 mg/mL methanol) at room temperature for 15 min in a 96-well black microtiter plate. Fluorescence was measured using excitation and emission wavelengths of 350 and 420 nm, respectively, in the Spetramax I3 equipment. Data were compared with those of the standard curve, normalized by the total protein content and expressed as a percentage of the control.

2.13. Glutamine Synthetase Activity

The medium was removed, and the cells were scraped in 50 mM imidazole. The enzymatic activity of glutamine synthetase (GS) was measured as previously described by [57], with modifications. Briefly, cell homogenates were diluted in 50 mM imidazole and incubated in the following manner: with (in mM) 50 imidazole, 50 hydroxylamine, 100 L-glutamine, 25 sodium arsenate dibasic heptahydrate, 0.2 ADP, 2 manganese chloride, pH 6.2 for 15 min at 37 °C. The reaction was stopped by adding 0.37 M FeCl₃, 0.67 M HCl and 200 mM C₂HCl₃O₂. After centrifugation, the absorbance of the supernatant was measured at 540 nm using the Spetramax I3 equipment and compared to the absorbance generated by standard quantities of L-glutamic acid γ -monohydroxamate diluted in the same solution as the samples. Data were normalized by the total protein content and expressed as a percentage of the control.

2.14. Western Blot Analysis

The medium was removed and the cells were scraped and homogenized in a sample buffer (0.0625 M tris-HCl, pH 6.8, 2% (*w/v*) SDS, 5% (*w/v*) β -mercaptoethanol, 10% (*v/v*) glycerol, 0.002% (*w/v*) bromophenol blue), boiled and then centrifuged at 10,000 $\times g$ for 5 min. Equal amounts (15 μ g) of total protein were electrophoresed in a 12% (*w/v*) SDS-polyacrylamide gel at 180 V for 1 h. The separated proteins were blotted onto a nitrocellulose membrane at an amperage of 1.2 mA/cm² membrane area. Membranes were incubated in 0.05 tween TBS (same composition as used in 2.9) (T-TBS), containing 5% fat-free milk powder diluted in TBS (*w/v*) for 1 h at 4 °C. The membranes were incubated overnight at 4 °C with the appropriate primary antibody (diluted 1:5000 in 2.5% bovine serum albumin). Afterward, membranes were incubated overnight at 4 °C with peroxidase-conjugated anti-rabbit antibody (dilution 1:10,000 in 2.5% bovine serum albumin). Equivalent loading of each sample was confirmed with 0.5% India ink dye (in T-TBS containing 1% acetic acid) for 3 h [58]. The chemiluminescence signal was detected using an ECL kit from Amersham and evaluated in the luminescence image analyzer (Image Quant LAS4000 from GE). The luminescence signals were analyzed using ImageJ software, and the optical density was normalized by India ink optical density values. Results were expressed as a percentage of control.

2.15. Protein Content

Protein content was determined by Lowry's method modified by Peterson, using bovine serum albumin as a standard [59]. This method was used to measure total protein content for S100B, GFAP, glutamate uptake, GS and GSH assays.

2.16. Statistical Analysis

All analyses were carried out on a PC-compatible computer using SPSS software version 20.0. Parametric or non-parametric tests were used according to the sample number, and the normal distribution and homogeneity of variances were performed by the Shapiro-Wilk and Levene tests, respectively. When normal distribution and homogeneity were

assumed, one-way analysis of variance (ANOVA), followed by Tukey post hoc testing, was performed to analyze 3 or more experimental groups. When homogeneity or normal distribution was not assumed, the non-parametric Mann–Whitney test was performed to analyze 2 experimental groups, or the Kruskal–Wallis test followed by pairwise comparison (Dunn–Bonferroni) to analyze 3 or more experimental groups. The statistical analyses are indicated in each of the figure legends. Significance was considered when $p < 0.05$.

3. Results

3.1. MG, FC, LPS and STZ Do Not Compromise Cell Viability, Integrity and Morphology

To evaluate whether MG, FC, LPS or STZ, compounds that mimic some conditions involved in brain injury mechanisms, cause cell damage, cultured astrocytes were exposed to 500 μM MG, 100 μM FC, 10 $\mu\text{g}/\text{mL}$ LPS or 250 μM STZ for 24 h before the assays. None of the compounds caused loss of cell viability, as evaluated by the MTT reduction and NR incorporation assays, or integrity, as assessed by measuring PI uptake and LDH extracellular activity. Interestingly, 100 μM (F [4, 40] = 17.903, $p < 0.001$) FC reduced LDH extracellular activity (Table 1). To evaluate if the compounds cause morphological changes, we analyzed the actin filaments assessed by the rhodamine phalloidin assay. After 24 h of exposure to 500 μM MG, 100 μM FC, 10 $\mu\text{g}/\text{mL}$ LPS or 250 μM STZ, astrocytes maintained the polygonal shape and organization of actin filaments compared to the vehicle and to the culture's morphological aspect before the treatment (basal) (Figure 2).

Table 1. Effects of MG, FC, LPS and STZ on cell viability and integrity.

	MG 500 μM	FC 100 μM	LPS 10 $\mu\text{g}/\text{mL}$	STZ 250 μM
MTT	102.5 \pm 3.3 ($p = 1$)	102.9 \pm 3.3 ($p = 0.645$)	99.4 \pm 2.1 ($p = 0.706$)	102.8 \pm 2.0 ($p = 1$)
NR	101.1 \pm 2.7 ($p = 1$)	107.1 \pm 1.1 ($p = 0.999$)	101.8 \pm 3.6 ($p = 1$)	100.9 \pm 4.0 ($p = 0.844$)
PI	103.5 \pm 2.4 ($p = 1$)	89.1 \pm 3.7 ($p = 0.074$)	97.5 \pm 3.4 ($p = 0.768$)	98.7 \pm 2.2 ($p = 0.875$)
LDH	101.0 \pm 5.3 ($p = 1$)	59.4 \pm 5.6 ($p < 0.001$) *	96.2 \pm 4.5 ($p = 0.819$)	97.1 \pm 4.7 ($p = 0.934$)

Statistical analyses were performed with one-way ANOVA followed by Tukey post hoc. Data are presented as mean \pm standard error. * indicates difference from vehicle ($n = 4-8$). ANOVA, analysis of variance; FC, fluorocitrate; LDH, lactate dehydrogenase extracellular activity; LPS, lipopolysaccharide; MG, methylglyoxal; MTT, methyl thiazolyl diphenyl-tetrazolium bromide reduction; NR, neutral red incorporation; PI, propidium iodide uptake; STZ, streptozotocin.




Figure 2. Morphological evaluation of astrocytes. Astrocytes were fixed before (10% FCS DMEM) or after (serum-free DMEM) exposure to 500 μM MG; 100 μM FC; 10 $\mu\text{g}/\text{mL}$ LPS or 250 μM STZ for 24 h for visualization. Representative images of phase contrast (A–F), actin staining with rhodamine phalloidin in red (G–L), nuclei staining with bisbenzimidazole in blue (M–R) and merged images (S–Y). Scale bar = 50 μm (shown in (A)). DMEM, Dulbecco's modified Eagle's medium; FCS, fetal calf serum; FC, fluorocitrate; LPS, lipopolysaccharide; MG, methylglyoxal; STZ, streptozotocin.

3.2. MG, FC, LPS and STZ Affect Astrocyte Protein Markers

S100B and GFAP are characteristic astrocyte proteins and can be altered by numerous pathological conditions. We evaluated the intracellular contents of GFAP and S100B, as well as the S100B secretion from cultured astrocytes after 24 h of exposure to different concentrations of MG (from 5 to 500 μM), FC (from 1 to 100 μM), LPS (from 0.1 to 10 $\mu\text{g}/\text{mL}$) or STZ (from 2.5 to 250 μM). These compounds caused a similar response profile of the astrocytes in terms of the S100B secretion and the contents of S100B and GFAP. We observed that 50 μM ($H[3] = 12.158, p = 0.031$) and 500 μM ($H[3] = 12.158, p = 0.022$) MG increased GFAP content (Figure 3A), and 500 μM ($H[3] = 13.280, p = 0.002$) MG caused a reduction in S100B secretion (Figure 3B). For FC, 10 μM ($H[3] = 16.856, p = 0.002$) and 100 μM ($H[3] = 12.158, p = 0.034$) (Figure 3D) increased GFAP content, and also 10 μM ($H[3] = 22.916, p = 0.040$) and 100 μM ($H[3] = 22.916, p < 0.001$) FC caused a reduction in S100B secretion (Figure 3E). For LPS, 10 $\mu\text{g}/\text{mL}$ ($H[3] = 11.507, p = 0.009$) (Figure 3G) increased GFAP content, and S100B secretion was found to be reduced by 10 $\mu\text{g}/\text{mL}$ ($H[3] = 13.789, p = 0.032$) LPS (Figure 3H). For STZ, the GFAP content was increased by 250 μM ($H[3] = 12.525, p = 0.003$) STZ (Figure 3J), 250 μM ($H[3] = 17.489, p < 0.001$) STZ caused a reduction in S100B secretion (Figure 3K), and only 250 μM ($F[3, 22] = 4.470, p = 0.040$) STZ caused a decrease in the astrocytes' S100B content (Figure 3L).




Figure 3. Effects of MG, FC, LPS and STZ on GFAP content, S100B secretion and S100B content. GFAP intracellular content, S100B secretion and S100B content were measured by ELISA in the astrocytes culture after 24 h of exposition to (A–C) MG (from 5 to 500 μM) ($n = 3–7$), (D–F) FC (from 1 to 100 μM) ($n = 5–6$), (G–I) LPS (from 0.1 to 10 $\mu\text{g}/\text{mL}$) ($n = 3–8$) or (J–L) STZ (from 2.5 to 250 μM) ($n = 3–10$). Statistical analysis was performed with the Kruskal–Wallis test followed by pairwise comparison (Dunn–Bonferroni) for (A,B,D,E,G,H,J,K) or one-way ANOVA followed by Tukey post hoc for (C,F,I,L). Data are presented as box-and-whiskers plots, where the bottom and the top of the box represent the min to max and the horizontal line is the median (when Kruskal–Wallis was applied). Data are presented as mean \pm standard error (when ANOVA was applied). * indicates difference from vehicle. ANOVA, analysis of variance; FC, fluorocitrate; GFAP, glial fibrillary acidic protein; LPS, lipopolysaccharide; MG, methylglyoxal; STZ, streptozotocin.

3.3. MG, FC, LPS and STZ Affect the Glutamate Metabolism of Astrocytes

Astrocytes have the important function of removing and metabolizing glutamate from the synaptic cleft, in addition to producing GSH. To evaluate whether this important

function of astrocytes is affected by different biochemical conditions associated with the brain injury process, we evaluated the glutamate uptake, GSH content and GS activity in astrocytes exposed to 500 μ M MG, 100 μ M FC, 10 μ g/mL LPS, or 250 μ M STZ for 24 h (Figure 4). MG (Figure 4A) did not affect astrocytic glutamate uptake, but increased GS activity (U < 0.001, p = 0.021) (Figure 4B) and GSH content (U = 30.000, p = 0.045) (Figure 4C). FC increased glutamate uptake (U = 5.000, p = 0.013) (Figure 4D), whereas it decreased GS activity (U = 3.000, p = 0.047) (Figure 4E) and GSH content (U = 17.000, p = 0.025) (Figure 4F). LPS decreased glutamate uptake (U = 2.000, p = 0.012) (Figure 4G), whereas it increased GS activity (U < 0.001, p = 0.021) (Figure 4H) and GSH content (U < 0.001, p = 0.021) (Figure 4I). STZ increased glutamate uptake (U = 3.000, p = 0.019) (Figure 4J), whereas it decreased GS activity (U = 0.000, p = 0.016) (Figure 4K) and GSH content (U = 6.000, p = 0.018) (Figure 4L).




Figure 4. Effects of MG, FC, LPS and STZ on astrocytic glutamate metabolism. Glutamate uptake, GS activity and GSH content were measured in the astrocytes culture after 24 h of exposition to (A–C) 500 μ M MG (n = 3–11), (D–F) 100 μ M FC (n = 5–7), (G–I) 10 μ g/mL LPS (n = 4–5) or (J–L) 250 μ M STZ (n = 5–8). Statistical analysis was performed with the Mann–Whitney test. Data are presented as box-and-whiskers plots, where the bottom and the top of the box represent the min to max, and the horizontal line is the median. * indicates difference from vehicle. FC, fluorocitrate; GS, glutamine synthetase; GSH, reduced glutathione; LPS, lipopolysaccharide; MG, methylglyoxal; STZ, streptozotocin.

3.4. Only LPS and STZ Affect Proteins Involved in the Amyloid Cascade

Astrocytes are involved in early alterations observed in neurodegenerative diseases, such as AD. To evaluate the role of astrocytes in the amyloid cascade, under our experimental conditions, we evaluated some of the proteins involved in the A β accumulation process (A β 1-40, IDE and NEP) in astrocytes exposed to 500 μ M MG, 100 μ M FC, 10 μ g/mL LPS, or 250 μ M STZ for 24 h. Only LPS and STZ altered the content of these proteins. LPS decreased the astrocytes' content of IDE (F[4, 15] = 8.420, p = 0.013) (Figure 5B). STZ increased the A β 1-40 peptide content (F[4, 21] = 3.039, p = 0.036) (Figure 5A), accompanied by a decrease in the content of the amyloid degradation enzymes, IDE (F[4, 15] = 8.420, p = 0.009) (Figure 5B) and NEP (F[4, 16] = 7.177, p = 0.026) (Figure 5C).




Figure 5. Effects of MG, FC, LPS and STZ on amyloid metabolism. Astrocyte cultures were exposed to 500 μM MG; 100 μM FC; 10 μg/mL LPS or 250 μM STZ for 24 h to evaluate the intracellular content of (A) Aβ₁₋₄₀ (n = 4–6), (B) IDE (n = 4) and (C) NEP (n = 4–5). In (D), representative images of immunoblots. Statistical analysis was performed with one-way ANOVA followed by Tukey post hoc. Data are presented as mean ± standard error. * indicates difference from vehicle. Aβ₁₋₄₀, amyloid beta; ANOVA, analysis of variance; FC, fluorocitrate; IDE, insulin-degrading enzyme; LPS, lipopolysaccharide; MG, methylglyoxal; NEP, neprilysin; STZ, streptozotocin.

4. Discussion

Astrocytes play a crucial role in maintaining brain homeostasis in the CNS, and dysfunction of astrocytes has been reported during the early phases of some brain disorders [3,46], emphasizing the importance of understanding the roles of astrocytic alterations in this context. Biochemical and metabolic alterations that cause or contribute to the development of cognitive impairment include glucose homeostasis disruption, neuroinflammation and the formation of protein aggregates [13]. As such, we selected four different compounds to mimic some important characteristics associated with the initiation or progression of cognitive disorders, aiming to study some astrocytic metabolic features within this context: MG (used to mimic high glucose and DM in vivo), FC (an inhibitor of energy metabolism), LPS (used to induce neuroinflammation), and STZ (used to induce AD in animal models).

To choose the concentration of use of the compounds, we first exposed the astrocyte cultures to different concentrations of MG, FC, LPS or STZ and evaluated the level of GFAP and S100B, which are frequently associated with brain disorders [9,60]. In fact, they seem to be an essential astrocytic response mechanism, as all of the stimuli tested on the astrocytes induced the same response profile: an increase in astrocytic GFAP levels and a decrease in S100B secretion without evidence of cell damage. A previous study from our group showed that hippocampal slices exposed to MG presented diminished S100B secretion; furthermore, in vivo, MG ICV administration modulated S100B in the short term (72 h) [25] but not over a more extended period (6 weeks) [24]. With regard to FC, reductions in S100B secretion have previously been observed in hippocampal slices and astrocyte cultures after 1 h of exposure [50]. We found that this effect persists until 24 h and

that astrocytes also exhibited increased GFAP. Interestingly, in animal models, FC reduced the elevation in GFAP caused by LPS in a depression-like model [61]. Corroborating our results, several studies have described the effects of LPS on S100B and GFAP in isolated astrocytes [49,62–65]. In STZ-induced AD, the increase in GFAP brain levels precedes A β accumulation and NFT formation [39,41,66]. Similarly, S100B, considered a cerebral damage marker, is increased in AD patients' serum, whereas its levels in the CSF demonstrate discrepant results (see Gonçalves et al., 2008 for a review). On the other hand, in STZ-induced AD, S100B is decreased in the CSF and elevated in the hippocampus within a short time after injection (one week) and increased in the CSF and decreased in the hippocampus after 4 weeks [67]. Similarly, in acute hippocampus slices, S100B was reduced by STZ after 1 h [41]. Our data corroborated these findings in cultured astrocytes. The significance of cerebral GFAP and S100B levels should be discussed according to the context [68]; here, considering situations involved with brain damage, all of the compounds tested showed a similar profile, suggesting astrocytic dysfunction, as found in neurodegenerative diseases.

Based on the effects observed on S100B and GFAP, we investigated astrocytic function, assessing some features related to glutamate and A β metabolism by the highest concentration of MG, FC, LPS or STZ. Astrocytes play an important role in glutamate detoxification via the glutamate–glutamine cycle, and dysfunctions in this system have been observed in cognitive disorders [10,69]. Mimicking a DM2 condition in astrocytes, MG increased GSH content and GS activity without affecting the glutamate uptake. This could represent a protective mechanism in astrocytes from MG, as previously observed in an astrocyte culture incubated with 1 mM MG, which was found to cause increases in GSH and glyoxalase 1 enzyme in association with a decrease in glutamate uptake [23]. The most prevalent type of dementia is AD, characterized, among other alterations, by A β accumulation due to an imbalance in its production and clearance. A β clearance by astrocytes plays a critical role in AD development, and a decreased rate of A β clearance has been reported in AD patients [70,71]. As such, astrocytes express enzymes that degrade A β , such as NEP and IDE [47,72]. Alterations in these enzymes during the early stages of AD have been reported as crucial to disease progression [45,47]. Glycation reactions are suggested to enhance A β formation pathways in amyloid precursor protein (APP) processing mechanisms [73], and the clearance of A β by astrocytes was impaired after inhibiting insulin signaling pathways, in turn reducing NEP and IDE levels [74]. Despite that, the alterations in glycation induced by MG in our conditions did not impact these targets involved in the A β metabolism.

The inhibition of energy metabolism by FC had a different profile regarding glutamate metabolism. In this scenario, we observed an increase in glutamate uptake, a decrease in GSH content and no change in GS enzyme activity. Previous studies showed an impairment of glutamate metabolism, leading to reductions in glutamate uptake and glutamine synthesis [75,76]. Paulsen and co-workers observed a similar result after 4 h of an intrastriatal administration of FC, which was reversed in 24 h [77]. Energy hypometabolism is found in AD patients, and evidence suggests this is important at the beginning of AD [78]. Although the effects of FC on AD are not entirely understood, in an animal model of AD induced by A β 1-42 injection in the hippocampus, FC was found to reduce the acquisition of spatial memory [79] and also increased tau phosphorylation in the hippocampus [80]. Regarding A β -metabolism and its accumulation, similarly to MG, FC did not cause any alteration in our conditions.

Inflammation is a crucial mechanism shared by many neurodegenerative diseases. The excitotoxicity and the increase in Ca⁺² influx in the neural cells may be caused by an impaired glutamate uptake by astrocytes. Accordingly, we observe that LPS-induced inflammation decreased glutamate uptake, suggesting an accumulation of glutamate in the synaptic cleft possibly leading to excitotoxicity, as shown in neuronal cell cultures, hippocampus slices and cerebral cortex tissue [81–83]. Further, we found an increase in GS enzyme activity and no alterations in GSH content in astrocytes. A decrease in GSH content was observed in cultured astrocytes exposed to LPS (from 0.01 to 30 μ g/mL, except at 1 μ g/mL) for 24 h [49]. Similarly, hippocampus slices exposed to 10 μ M/mL LPS for 6 h

showed a reduction in glutamate uptake and GSH content [83]. Different from what we observed for MG and FC, LPS induced a decrease in IDE protein expression in astrocytes without changes in A β intracellular content. Indeed, neuroinflammation is reported to represent a critical alteration in AD development [84,85]. The role of inflammation in the amyloidogenic pathway was indicated in astrocytes by the increased expressions of proteins such as APP and BACE [86]. We demonstrated that LPS is also involved in AD development by impairing the A β clearance mechanisms of astrocytes before the accumulation of A β .

ICV injection of STZ is widely used as a model of AD in animals, although most in vitro models have explored its effect on neurons [51,87,88]. The mechanisms by which STZ induces AD development are not fully understood, but it has been proposed that this compound can enter neurons through GLUT2 and affect the insulin receptor, thereby improving the GSK3 pathway [89]. After exposing the astrocytes to STZ, we found an increase in glutamate uptake, but decreased GSH levels and GS activity. Indeed, the effects of STZ on GSH and GS have been extensively shown in animal models from 1 to 8 weeks after STZ administration [43,68,90]. In this work, we showed, for the first time, that these effects are directly related to astrocyte function. An in vivo study measured glutamate uptake in hippocampal slices 4 weeks after STZ administration, and it was not altered. Notably, at this stage, the animal already shows some late alterations consistent with AD, such as cognitive damage [90]. In isolated astrocytes, an increase in glutamate uptake was observed at 24 h, probably indicating a compensatory mechanism during the early stages. Regarding A β metabolism, STZ was the only compound tested in this work that caused a reduction in IDE and NEP protein contents associated with an increase in A β 1-40 content. In previous work using neuronal primary culture, 8 mM STZ increased the mRNA expressions of APP, MAPT, GSK3 α and GSK3 β at 24 h; all of these pathways are involved in A β production and tau phosphorylation [87]. Herein, we showed that STZ could directly affect astrocytic mechanisms involved in AD, such as clearance by NEP and IDE, and therefore contribute to A β accumulation.

It is worth highlighting that the profile of alterations caused by the model using STZ ICV injection to induce AD in animals was reproduced in isolated astrocytes in this study regarding GFAP, S100B, GS and GSH measurements. In addition, our data related to amyloid metabolism showed a direct response of astrocytes to STZ in the AD context. Together, these findings suggest that the use of STZ is appropriate for the study of the role of astrocytes in AD in an in vitro model.

5. Conclusions

We showed that high glucose concentrations, astrocyte inhibition, neuroinflammation and AD development characteristics mimicked by MG, FC, LPS and STZ caused astrocyte activation and decreased S100B secretion. However, the insults used affected the glutamate metabolism of astrocytes differently, and only STZ reduced both the A β degrading enzymes, NEP and IDE, and caused elevations in A β levels. Thus, all of the compounds affect astrocytes, altering cellular functions and contributing to the progression of brain disorders such as AD, but STZ seems to provide a better model to study the role of astrocytes in some features of AD in vitro.

Author Contributions: J.T., M.C.L. and C.A.G.; conception and design of the work. J.T., F.T.F. and M.S.; data collection. J.T., M.C.L., C.A.G., F.T.F. and M.S.; analysis and interpretation. M.C.L. and C.A.G.; funding acquisition. J.T., M.C.L. and C.A.G.; writing the paper. All authors have read and agreed to the published version of the manuscript.

Funding: This research was funded by Conselho Nacional de Desenvolvimento Científico e Tecnológico (CNPq), grant number 430752/2018-0; Coordenação de Aperfeiçoamento de Pessoal de Nível Superior (CAPES), grant number 001; Fundação de Amparo à Pesquisa do Estado do Rio Grande do Sul (FAPERGS), grant number 16/0465-0 and Instituto Nacional de Ciência e Tecnologia para Excitotoxicidade e Neuroproteção (INCTEN), grant number 465671/2014-4.

Institutional Review Board Statement: The procedures were in accordance with the National Institutes of Health Guide for the Care and Use of Laboratory Animals and approved by the local authorities (number 34855, approved on 18 September 2018).

Informed Consent Statement: Not applicable.

Data Availability Statement: The raw data supporting the results of this study are, by collective decision of the authors, available from the corresponding author [MC Leite] upon request.

Conflicts of Interest: The authors declare that they have no competing interests.

References

1. Pekny, M.; Pekna, M.; Messing, A.; Steinhäuser, C.; Lee, J.M.; Parpura, V.; Hol, E.M.; Sofroniew, M.V.; Verkhratsky, A. Astrocytes: A Central Element in Neurological Diseases. *Acta Neuropathol.* **2016**, *131*, 323–345. [\[CrossRef\]](#)
2. Blanco-Suárez, E.; Caldwell, A.L.M.; Allen, N.J. Role of Astrocyte–Synapse Interactions in CNS Disorders. *J. Physiol.* **2017**, *595*, 1903–1916. [\[CrossRef\]](#)
3. Chung, W.-S.; Welsh, C.A.; Barres, B.A.; Stevens, B. Do Glia Drive Synaptic and Cognitive Impairment in Disease? *Nat. Neurosci.* **2015**, *18*, 1539–1545. [\[CrossRef\]](#)
4. Pérez Palmer, N.; Trejo Ortega, B.; Joshi, P. Cognitive Impairment in Older Adults: Epidemiology, Diagnosis, and Treatment. *Psychiatr. Clin. N. Am.* **2022**, *45*, 639–661. [\[CrossRef\]](#)
5. Gauthier, S.; Webster, C.; Servaes, S.; Morais, J.A.; Rosa-Neto, P. *World Alzheimer Report 2022: Life after Diagnosis: Navigating Treatment, Care and Support*; Alzheimer’s Disease International: London, UK, 2022; pp. 1–414.
6. Rae, C.D.; Baur, J.A.; Borges, K.; Dienel, G.; Díaz, C.M.; Starlette, G.; Kelly, R.D.; Duarte, J.M.N.; Liu, D.L.; Lindquist, B.E.; et al. Brain Energy Metabolism: A Roadmap for Future Research. *J. Neurochem.* **2024**, 1–45. [\[CrossRef\]](#)
7. Santello, M.; Toni, N.; Volterra, A. Astrocyte Function from Information Processing to Cognition and Cognitive Impairment. *Nat. Neurosci.* **2019**, *22*, 154–166. [\[CrossRef\]](#)
8. Donato, R. S100: A Multigenic Family of Calcium-Modulated Proteins of the EF-Hand Type with Intracellular and Extracellular Functional Roles. *Int. J. Biochem. Cell Biol.* **2001**, *33*, 637–668. [\[CrossRef\]](#)
9. Escartin, C.; Galea, E.; Lakatos, A.; O’Callaghan, J.P.; Petzold, G.C.; Serrano-Pozo, A.; Steinhäuser, C.; Volterra, A.; Carmignoto, G.; Agarwal, A.; et al. Reactive Astrocyte Nomenclature, Definitions, and Future Directions. *Nat. Neurosci.* **2021**, *24*, 312–325. [\[CrossRef\]](#)
10. Andersen, J.V.; Markussen, K.H.; Jakobsen, E.; Schousboe, A.; Waagepetersen, H.S.; Rosenberg, P.A.; Aldana, B.I. Glutamate Metabolism and Recycling at the Excitatory Synapse in Health and Neurodegeneration. *Neuropharmacology* **2021**, *196*, 108719. [\[CrossRef\]](#)
11. Palmer, A.L.; Ousman, S.S. Astrocytes and Aging. *Front. Aging Neurosci.* **2018**, *10*, 337. [\[CrossRef\]](#)
12. Leclerc, B.; Abulrob, A. Perspectives in Molecular Imaging Using Staging Biomarkers and Immunotherapies in Alzheimer’s Disease. *Sci. World J.* **2013**, *2013*, 589308–589323. [\[CrossRef\]](#)
13. Gonzales, M.M.; Garbarino, V.R.; Pollet, E.; Palavicini, J.P.; Kellogg, D.L.; Kraig, E.; Orr, M.E. Biological Aging Processes Underlying Cognitive Decline and Neurodegenerative Disease. *J. Clin. Investig.* **2022**, *132*, e158453. [\[CrossRef\]](#)
14. Hassel, B.; Westergaard, N.; Schousboe, A.; Fonnum, F. Metabolic Differences between Primary Cultures of Astrocytes and Neurons from Cerebellum and Cerebral Cortex. Effects of Fluorocitrate. *Neurochem. Res.* **1995**, *20*, 413–420. [\[CrossRef\]](#)
15. Zhang, X.; Shen, X.; Dong, J.; Liu, W.C.; Song, M.; Sun, Y.; Shu, H.; Towse, C.L.; Liu, W.; Liu, C.F.; et al. Inhibition of Reactive Astrocytes with Fluorocitrate Ameliorates Learning and Memory Impairment Through Upregulating CRT1 and Synaptophysin in Ischemic Stroke Rats. *Cell. Mol. Neurobiol.* **2019**, *39*, 1151–1163. [\[CrossRef\]](#)
16. Zhang, H.Y.; Wang, Y.; He, Y.; Wang, T.; Huang, X.H.; Zhao, C.M.; Zhang, L.; Li, S.W.; Wang, C.; Qu, Y.N.; et al. A1 Astrocytes Contribute to Murine Depression-like Behavior and Cognitive Dysfunction, Which Can Be Alleviated by IL-10 or Fluorocitrate Treatment. *J. Neuroinflamm.* **2020**, *17*, 200. [\[CrossRef\]](#)
17. Rezagholizadeh, A.; Karimi, S.A.; Hosseinmardi, N.; Janahmadi, M.; Sayyah, M. The Effects of Glial Cells Inhibition on Spatial Reference, Reversal and Working Memory Deficits in a Rat Model of Traumatic Brain Injury (TBI). *Int. J. Neurosci.* **2022**, *132*, 226–236. [\[CrossRef\]](#)
18. Rae, C.; Fekete, A.D.; Kashem, M.A.; Nasrallah, F.A.; Bröer, S. Metabolism, Compartmentation, Transport and Production of Acetate in the Cortical Brain Tissue Slice. *Neurochem. Res.* **2012**, *37*, 2541–2553. [\[CrossRef\]](#)
19. Jash, K.; Gondaliya, P.; Kirave, P.; Kulkarni, B.; Sunkaria, A.; Kalia, K. Cognitive Dysfunction: A Growing Link between Diabetes and Alzheimer’s Disease. *Drug Dev. Res.* **2020**, *81*, 144–164. [\[CrossRef\]](#)
20. Shopit, A.; Niu, M.; Wang, H.; Tang, Z.; Li, X.; Tesfaldet, T.; Ai, J.; Ahmad, N.; Al-Azab, M.; Tang, Z. Protection of Diabetes-Induced Kidney Injury by Phosphocreatine via the Regulation of ERK/Nrf₂/HO-1 Signaling Pathway. *Life Sci.* **2020**, *242*, 117248. [\[CrossRef\]](#)
21. Cho, C.H.; Lee, C.J.; Kim, M.G.; Ryu, B.; Je, J.G.; Kim, Y.; Lee, S.H. Therapeutic Potential of Phlorotannin-Rich Ecklonia Cava Extract on Methylglyoxal-Induced Diabetic Nephropathy in In Vitro Model. *Mar. Drugs* **2022**, *20*, 355. [\[CrossRef\]](#)

22. Karumanchi, D.K.; Karunaratne, N.; Lurio, L.; Dillon, J.P.; Gaillard, E.R. Non-Enzymatic Glycation of α -Crystallin as an in Vitro Model for Aging, Diabetes and Degenerative Diseases. *Amino Acids* **2015**, *47*, 2601–2608. [[CrossRef](#)]
23. Hansen, F.; Galland, F.; Lirio, F.; De Souza, D.F.; Da Ré, C.; Pacheco, R.F.; Vizuite, A.F.; Quincozes-Santos, A.; Leite, M.C.; Gonçalves, C.A. Methylglyoxal Induces Changes in the Glyoxalase System and Impairs Glutamate Uptake Activity in Primary Astrocytes. *Oxid. Med. Cell Longev.* **2017**, *2017*, 9574201–9574211. [[CrossRef](#)]
24. Hansen, F.; Pandolfo, P.; Galland, F.; Torres, F.V.; Dutra, M.F.; Batassini, C.; Guerra, M.C.; Leite, M.C.; Gonçalves, C.A. Methylglyoxal Can Mediate Behavioral and Neurochemical Alterations in Rat Brain. *Physiol. Behav.* **2016**, *164*, 93–101. [[CrossRef](#)]
25. Lissner, L.J.; Rodrigues, L.; Wartchow, K.M.; Borba, E.; Bobermin, L.D.; Fontella, F.U.; Hansen, F.; Quincozes-Santos, A.; Souza, D.O.G.; Gonçalves, C.A. Short-Term Alterations in Behavior and Astroglial Function after Intracerebroventricular Infusion of Methylglyoxal in Rats. *Neurochem. Res.* **2021**, *46*, 183–196. [[CrossRef](#)]
26. Allaman, I.; Bélanger, M.; Magistretti, P.J. Methylglyoxal, the Dark Side of Glycolysis. *Front. Neurosci.* **2015**, *9*, 23. [[CrossRef](#)]
27. Ott, C.; Jacobs, K.; Haucke, E.; Navarrete Santos, A.; Grune, T.; Simm, A. Role of Advanced Glycation End Products in Cellular Signaling. *Redox Biol.* **2014**, *2*, 411–429. [[CrossRef](#)]
28. Hofmann, M.A.; Drury, S.; Fu, C.; Qu, W.; Taguchi, A.; Lu, Y.; Avila, C.; Kambham, N.; Bierhaus, A.; Nawroth, P.; et al. RAGE Mediates a Novel Proinflammatory Axis: A Central Cell Surface Receptor for S100/Calgranulin Polypeptides. *Cell* **1999**, *97*, 889–901. [[CrossRef](#)]
29. Hansen, F.; Battú, C.E.; Dutra, M.F.; Galland, F.; Lirio, F.; Broetto, N.; Nardin, P.; Gonçalves, C.A. Methylglyoxal and Carboxyethyllysine Reduce Glutamate Uptake and S100B Secretion in the Hippocampus Independently of RAGE Activation. *Amino Acids* **2016**, *48*, 375–385. [[CrossRef](#)]
30. Angeloni, C.; Zamboni, L.; Hrelia, S. Role of Methylglyoxal in Alzheimer's Disease. *BioMed Res. Int.* **2014**, *2014*, 238485. [[CrossRef](#)]
31. Shi, D.Y.; Bierhaus, A.; Nawroth, P.P.; Stern, D.M. RAGE and Alzheimer's Disease: A Progression Factor for Amyloid- β -Induced Cellular Perturbation? *J. Alzheimer's Dis.* **2009**, *16*, 833–843. [[CrossRef](#)]
32. Stephenson, J.; Nutma, E.; van der Valk, P.; Amor, S. Inflammation in CNS Neurodegenerative Diseases. *Immunology* **2018**, *154*, 204–219. [[CrossRef](#)]
33. Singh, S.; Sahu, K.; Singh, C.; Singh, A. Lipopolysaccharide Induced Altered Signaling Pathways in Various Neurological Disorders. *Naunyn. Schmiedebergs. Arch. Pharmacol.* **2022**, *395*, 285–294. [[CrossRef](#)]
34. Zakaria, R.; Wan Yaacob, W.M.; Othman, Z.; Long, I.; Ahmad, A.H.; Al-Rahbi, B. Lipopolysaccharide-Induced Memory Impairment in Rats: A Model of Alzheimer's Disease. *Physiol. Res.* **2017**, *66*, 553–565. [[CrossRef](#)]
35. Płóciennikowska, A.; Hromada-Judycka, A.; Borzęcka, K.; Kwiatkowska, K. Co-Operation of TLR4 and Raft Proteins in LPS-Induced pro-Inflammatory Signaling. *Cell. Mol. Life Sci.* **2015**, *72*, 557–581. [[CrossRef](#)]
36. Trotta, T.; Porro, C.; Calvello, R.; Panaro, M.A. Biological Role of Toll-like Receptor-4 in the Brain. *J. Neuroimmunol.* **2014**, *268*, 1–12. [[CrossRef](#)]
37. Masters, C.L.; Bateman, R.; Blennow, K.; Rowe, C.C.; Sperling, R.A.; Cummings, J.L. Alzheimer's Disease. *Nat. Rev. Dis. Prim.* **2015**, *1*, 15056. [[CrossRef](#)]
38. De Strooper, B.; Karran, E. The Cellular Phase of Alzheimer's Disease. *Cell* **2016**, *164*, 603–615. [[CrossRef](#)]
39. Mishra, S.K.; Singh, S.; Shukla, S.; Shukla, R. Intracerebroventricular Streptozotocin Impairs Adult Neurogenesis and Cognitive Functions via Regulating Neuroinflammation and Insulin Signaling in Adult Rats. *Neurochem. Int.* **2018**, *113*, 56–68. [[CrossRef](#)]
40. Huf, F.; Gutierrez, J.M.; da Silva, G.N.; Zago, A.M.; Koening, L.F.C.; Fernandes, M.C. Neuroprotection Elicited by Taurine in Sporadic Alzheimer-like Disease: Benefits on Memory and Control of Neuroinflammation in the Hippocampus of Rats. *Mol. Cell. Biochem.* **2023**, *2023*, 1–16. [[CrossRef](#)]
41. Rodrigues, L.; Wartchow, K.M.; Suardi, L.Z.; Federhen, B.C.; Selistre, N.G.; Gonçalves, C.A. Streptozotocin Causes Acute Responses on Hippocampal S100B and BDNF Proteins Linked to Glucose Metabolism Alterations. *Neurochem. Int.* **2019**, *128*, 85–93. [[CrossRef](#)]
42. Akhtar, A.; Gupta, S.M.; Dwivedi, S.; Kumar, D.; Shaikh, M.F.; Negi, A. Preclinical Models for Alzheimer's Disease: Past, Present, and Future Approaches. *ACS Omega* **2022**, *7*, 47504–47517. [[CrossRef](#)]
43. Rodrigues, L.; Biasibetti, R.; Swarowsky, A.; Leite, M.C.; Quincozes-Santos, A.; Quilfeldt, J.A.; Achaval, M.; Goncalves, C.A. Hippocampal Alterations in Rats Submitted to Streptozotocin-Induced Dementia Model Are Prevented by Aminoguanidine. *J. Alzheimer's Dis.* **2009**, *17*, 193–202. [[CrossRef](#)]
44. Grieb, P. Intracerebroventricular Streptozotocin Injections as a Model of Alzheimer's Disease: In Search of a Relevant Mechanism. *Mol. Neurobiol.* **2016**, *53*, 1741–1752. [[CrossRef](#)]
45. Davis, N.; Mota, B.C.; Stead, L.; Palmer, E.O.C.; Lombardero, L.; Rodríguez-Puertas, R.; de Paola, V.; Barnes, S.J.; Sastre, M. Pharmacological Ablation of Astrocytes Reduces A β Degradation and Synaptic Connectivity in an Ex Vivo Model of Alzheimer's Disease. *J. Neuroinflamm.* **2021**, *18*, 73. [[CrossRef](#)]
46. Frost, G.R.; Li, Y.M. The Role of Astrocytes in Amyloid Production and Alzheimer's Disease. *Open Biol.* **2017**, *7*, 170228. [[CrossRef](#)]
47. Wyss-Coray, T.; Loike, J.D.; Brionne, T.C.; Lu, E.; Anankov, R.; Yan, F.; Silverstein, S.C.; Husemann, J. Adult Mouse Astrocytes Degrade Amyloid- β In Vitro and In Situ. *Nat. Med.* **2003**, *9*, 453–457. [[CrossRef](#)]

48. Gottfried, C.; Valentim, L.; Salbego, C.; Karl, J.; Wofchuk, S.T.; Rodnigh, R. Regulation of Protein Phosphorylation in Astrocyte Cultures by External Calcium Ions: Specific Effects on the Phosphorylation of Glial Fibrillary Acidic Protein (GFAP), Vimentin and Heat Shock Protein 27 (HSP27). *Brain Res.* **1999**, *833*, 142–149. [[CrossRef](#)]
49. Guerra, M.C.; Tortorelli, L.S.; Galland, F.; Da Ré, C.; Negri, E.; Engelke, D.S.; Rodrigues, L.; Leite, M.C.; Gonçalves, C.A. Lipopolysaccharide Modulates Astrocytic S100B Secretion: A Study in Cerebrospinal Fluid and Astrocyte Cultures from Rats. *J. Neuroinflamm.* **2011**, *8*, 128. [[CrossRef](#)]
50. Selistre, N.G.; Rodrigues, L.; Federhen, B.C.; Gayger-Dias, V.; Taday, J.; Wartchow, K.M.; Gonçalves, C.-A. S100B Secretion in Astrocytes, Unlike C6 Glioma Cells, Is Downregulated by Lactate. *Metabolites* **2023**, *14*, 7. [[CrossRef](#)]
51. Plaschke, K.; Kopitz, J. In Vitro Streptozotocin Model for Modeling Alzheimer-like Changes: Effect on Amyloid Precursor Protein Secretases and Glycogen Synthase Kinase-3. *J. Neural Transm.* **2015**, *122*, 551–557. [[CrossRef](#)]
52. Leite, M.C.; Galland, F.; Brolese, G.; Guerra, M.C.; Bortolotto, J.W.; Freitas, R.; de Almeida, L.M.V.; Gottfried, C.; Gonçalves, C.A. A Simple, Sensitive and Widely Applicable ELISA for S100B: Methodological Features of the Measurement of This Glial Protein. *J. Neurosci. Methods* **2008**, *169*, 93–99. [[CrossRef](#)]
53. Tramontina, F.; Leite, M.C.; Cereser, K.; de Souza, D.F.; Tramontina, A.C.; Nardin, P.; Andrezza, A.C.; Gottfried, C.; Kapczinski, F.; Gonçalves, C.A. Immunoassay for Glial Fibrillary Acidic Protein: Antigen Recognition Is Affected by Its Phosphorylation State. *J. Neurosci. Methods* **2007**, *162*, 282–286. [[CrossRef](#)]
54. Gottfried, C.; Tramontina, F.; Gonçalves, D.; Gonçalves, C.A.; Moriguchi, E.; Dias, R.D.; Wofchuk, S.T.; Souza, D.O. Glutamate Uptake in Cultured Astrocytes Depends on Age: A Study about the Effect of Guanosine and the Sensitivity to Oxidative Stress Induced by H₂O₂. *Mech. Ageing Dev.* **2002**, *123*, 1333–1340. [[CrossRef](#)] [[PubMed](#)]
55. Thomazi, A.P.; Godinho, G.F.R.S.; Rodrigues, J.M.; Schwalm, F.D.; Frizzo, M.E.S.; Moriguchi, E.; Souza, D.O.; Wofchuk, S.T. Ontogenetic Profile of Glutamate Uptake in Brain Structures Slices from Rats: Sensitivity to Guanosine. *Mech. Ageing Dev.* **2004**, *125*, 475–481. [[CrossRef](#)] [[PubMed](#)]
56. Browne, R.W.; Armstrong, D. Reduced Glutathione and Glutathione Disulfide. *Methods Mol. Biol.* **1998**, *108*, 347–352. [[CrossRef](#)] [[PubMed](#)]
57. Minet, R.; Villie, F.; Marcollet, M.; Meynial-Denis, D.; Cynober, L. Measurement of Glutamine Synthetase Activity in Rat Muscle by a Colorimetric Assay. *Clin. Chim. Acta* **1997**, *268*, 121–132. [[CrossRef](#)] [[PubMed](#)]
58. Hancock, K.; Tsang, V.C. India Ink Staining of Proteins on Nitrocellulose Paper. *Anal. Biochem.* **1983**, *133*, 157–162. [[CrossRef](#)] [[PubMed](#)]
59. Peterson, G.L. A Simplification of the Protein Assay Method of Lowry et al. Which Is More Generally Applicable. *Anal. Biochem.* **1977**, *83*, 346–356. [[CrossRef](#)] [[PubMed](#)]
60. Carter, S.F.; Herholz, K.; Rosa-Neto, P.; Pellerin, L.; Nordberg, A.; Zimmer, E.R. Astrocyte Biomarkers in Alzheimer’s Disease. *Trends Mol. Med.* **2019**, *25*, 77–95. [[CrossRef](#)] [[PubMed](#)]
61. Wang, Y.; Ni, J.; Zhai, L.; Gao, C.; Xie, L.; Zhao, L.; Yin, X. Inhibition of Activated Astrocyte Ameliorates Lipopolysaccharide-Induced Depressive-like Behaviors. *J. Affect. Disord.* **2019**, *242*, 52–59. [[CrossRef](#)]
62. Seminotti, B.; Amaral, A.U.; Grings, M.; Ribeiro, C.A.J.; Leipnitz, G.; Wajner, M. Lipopolysaccharide-Elicited Systemic Inflammation Induces Selective Vulnerability of Cerebral Cortex and Striatum of Developing Glutaryl-CoA Dehydrogenase Deficient (Gcdh^{-/-}) Mice to Oxidative Stress. *Neurotox. Res.* **2020**, *38*, 1024–1036. [[CrossRef](#)]
63. Goshi, N.; Morgan, R.K.; Lein, P.J.; Seker, E. A Primary Neural Cell Culture Model to Study Neuron, Astrocyte, and Microglia Interactions in Neuroinflammation. *J. Neuroinflamm.* **2020**, *17*, 155. [[CrossRef](#)]
64. Dourado, N.S.; Souza, C.D.S.; de Almeida, M.M.A.; Bispo da Silva, A.; dos Santos, B.L.; Silva, V.D.A.; De Assis, A.M.; da Silva, J.S.; Souza, D.O.; Costa, M.d.F.D.; et al. Neuroimmunomodulatory and Neuroprotective Effects of the Flavonoid Apigenin in In Vitro Models of Neuroinflammation Associated with Alzheimer’s Disease. *Front. Aging Neurosci.* **2020**, *12*, 119. [[CrossRef](#)] [[PubMed](#)]
65. Oliveira-Junior, M.S.; Pereira, E.P.; de Amorim, V.C.M.; Reis, L.T.C.; do Nascimento, R.P.; da Silva, V.D.A.; Costa, S.L. Lupeol Inhibits LPS-Induced Neuroinflammation in Cerebellar Cultures and Induces Neuroprotection Associated to the Modulation of Astrocyte Response and Expression of Neurotrophic and Inflammatory Factors. *Int. Immunopharmacol.* **2019**, *70*, 302–312. [[CrossRef](#)] [[PubMed](#)]
66. Luo, H.; Xiang, Y.; Qu, X.; Liu, H.; Liu, C.; Li, G.; Han, L.; Qin, X. Apelin-13 Suppresses Neuroinflammation against Cognitive Deficit in a Streptozotocin-Induced Rat Model of Alzheimer’s Disease through Activation of BDNF-TrkB Signaling Pathway. *Front. Pharmacol.* **2019**, *10*, 395. [[CrossRef](#)]
67. Dos Santos, J.P.A.; Vizuete, A.; Hansen, F.; Biasibetti, R.; Gonçalves, C.A. Early and Persistent O-GlcNAc Protein Modification in the Streptozotocin Model of Alzheimer’s Disease. *J. Alzheimer’s Dis.* **2018**, *61*, 237–249. [[CrossRef](#)]
68. Gonçalves, C.A.; Concli Leite, M.; Nardin, P. Biological and Methodological Features of the Measurement of S100B, a Putative Marker of Brain Injury. *Clin. Biochem.* **2008**, *41*, 755–763. [[CrossRef](#)]
69. Sood, A.; Preeti, K.; Fernandes, V.; Khatri, D.K.; Singh, S.B. Glia: A Major Player in Glutamate–GABA Dysregulation-Mediated Neurodegeneration. *J. Neurosci. Res.* **2021**, *99*, 3148–3189. [[CrossRef](#)]
70. Mawuenyega, K.G.; Sigurdson, W.; Ovod, V.; Munsell, L.; Kasten, T.; Morris, J.C.; Yarasheski, K.E.; Bateman, R.J. Decreased Clearance of CNS β -Amyloid in Alzheimer’s Disease. *Science (80-)* **2010**, *330*, 1774. [[CrossRef](#)]
71. Miners, J.S.; Baig, S.; Palmer, J.; Palmer, L.E.; Kehoe, P.G.; Love, S. A β -Degrading Enzymes in Alzheimer’s Disease. *Brain Pathol.* **2008**, *18*, 240–252. [[CrossRef](#)] [[PubMed](#)]

72. Ries, M.; Sastre, M. Mechanisms of A β Clearance and Degradation by Glial Cells. *Front. Aging Neurosci.* **2016**, *8*, 160. [[CrossRef](#)]
73. Patil, G.V.; Joshi, R.S.; Kazi, R.S.; Kulsange, S.E.; Kulkarni, M.J. A Possible Role of Glycation in the Regulation of Amyloid β Precursor Protein Processing Leading to Amyloid β Accumulation. *Med. Hypotheses* **2020**, *142*, 109799. [[CrossRef](#)]
74. Yamamoto, N.; Ishikuro, R.; Tanida, M.; Suzuki, K.; Ikeda-Matsuo, Y.; Sobue, K. Insulin-Signaling Pathway Regulates the Degradation of Amyloid β -Protein via Astrocytes. *Neuroscience* **2018**, *385*, 227–236. [[CrossRef](#)]
75. Adermark, L.; Lagström, O.; Loftén, A.; Licheri, V.; Havenäng, A.; Loi, E.A.; Stomberg, R.; Söderpalm, B.; Domi, A.; Ericson, M. Astrocytes Modulate Extracellular Neurotransmitter Levels and Excitatory Neurotransmission in Dorsolateral Striatum via Dopamine D2 Receptor Signaling. *Neuropsychopharmacology* **2022**, *47*, 1493–1502. [[CrossRef](#)]
76. Swanson, R.A.; Graham, S.H. Fluorocitrate and Fluoroacetate Effects on Astrocyte Metabolism in Vitro. *Brain Res.* **1994**, *664*, 94–100. [[CrossRef](#)]
77. Paulsen, R.E.; Contestabile, A.; Villani, L.; Fonnum, F. An In Vivo Model for Studying Function of Brain Tissue Temporarily Devoid of Glial Cell Metabolism: The Use of Fluorocitrate. *J. Neurochem.* **1987**, *48*, 1377–1385. [[CrossRef](#)] [[PubMed](#)]
78. Raut, S.; Bhalerao, A.; Powers, M.; Gonzalez, M.; Mancuso, S.; Cucullo, L. Hypometabolism, Alzheimer's Disease, and Possible Therapeutic Targets: An Overview. *Cells* **2023**, *12*, 2019. [[CrossRef](#)]
79. Nikkar, R.; Esmaeili-bandboni, A.; Badrikoochi, M.; Babaei, P. Effects of Inhibiting Astrocytes and BET/BRD4 Chromatin Reader on Spatial Memory and Synaptic Proteins in Rats with Alzheimer's Disease. *Metab. Brain Dis.* **2022**, *37*, 1119–1131. [[CrossRef](#)] [[PubMed](#)]
80. Shang, X.L.; Wang, Q.B.; Liu, X.P.; Yao, X.Q.; Cao, F.Y.; Wang, Q.; Zhang, J.Y.; Wang, J.Z.; Liu, G.P. Fluorocitrate Induced the Alterations of Memory-Related Proteins and Tau Hyperphosphorylation in SD Rats. *Neurosci. Lett.* **2015**, *584*, 230–235. [[CrossRef](#)] [[PubMed](#)]
81. Bakaeva, Z.; Lizunova, N.; Tarzhanov, I.; Boyarkin, D.; Petrichuk, S.; Pinelis, V.; Fisenko, A.; Tuzikov, A.; Sharipov, R.; Surin, A. Lipopolysaccharide from *E. Coli* Increases Glutamate-Induced Disturbances of Calcium Homeostasis, the Functional State of Mitochondria, and the Death of Cultured Cortical Neurons. *Front. Mol. Neurosci.* **2022**, *14*, 811171. [[CrossRef](#)] [[PubMed](#)]
82. Wang, Y.S.; White, T.D. The Bacterial Endotoxin Lipopolysaccharide Causes Rapid Inappropriate Excitation in Rat Cortex. *J. Neurochem.* **1999**, *72*, 652–660. [[CrossRef](#)]
83. Vizuete, A.F.K.; Fróes, F.; Seady, M.; Zanotto, C.; Bobermin, L.D.; Roginski, A.C.; Wajner, M.; Quincozes-Santos, A.; Gonçalves, C.A. Early Effects of LPS-Induced Neuroinflammation on the Rat Hippocampal Glycolytic Pathway. *J. Neuroinflamm.* **2022**, *19*, 255. [[CrossRef](#)]
84. Leng, F.; Edison, P. Neuroinflammation and Microglial Activation in Alzheimer Disease: Where Do We Go from Here? *Nat. Rev. Neurol.* **2021**, *17*, 157–172. [[CrossRef](#)]
85. Heneka, M.T.; Carson, M.J.; El Khoury, J.; Landreth, G.E.; Brosseron, F.; Feinstein, D.L.; Jacobs, A.H.; Wyss-Coray, T.; Vitorica, J.; Ransohoff, R.M.; et al. Neuroinflammation in Alzheimer's Disease. *Lancet Neurol.* **2015**, *14*, 388–405. [[CrossRef](#)]
86. Lee, J.W.; Lee, Y.K.; Yuk, D.Y.; Choi, D.Y.; Ban, S.B.; Oh, K.W.; Hong, J.T. Neuro-Inflammation Induced by Lipopolysaccharide Causes Cognitive Impairment through Enhancement of Beta-Amyloid Generation. *J. Neuroinflamm.* **2008**, *5*, 37. [[CrossRef](#)] [[PubMed](#)]
87. Bhuvanendran, S.; Paudel, Y.N.; Kumari, Y.; Othman, I.; Shaikh, M.F. Embelin Prevents Amyloid-Beta Accumulation via Modulation of SOD1 in a Streptozotocin-Induced AD-like Condition: An Evidence from in Vitro Investigation. *Curr. Res. Neurobiol.* **2022**, *3*, 100032. [[CrossRef](#)] [[PubMed](#)]
88. Bagaméry, F.; Varga, K.; Kecsmár, K.; Vincze, I.; Szökő, É.; Tábi, T. Lack of Insulin Resistance in Response to Streptozotocin Treatment in Neuronal SH-SY5Y Cell Line. *J. Neural Transm.* **2020**, *127*, 71–80. [[CrossRef](#)] [[PubMed](#)]
89. Rodrigues, L.; Biasibetti, R.; Swarowsky, A.; Leite, M.; Quincozes-Santos, A.; Achaval, M.; Gonçalves, C.A. Hippocampal Alterations in Rats Submitted to Streptozotocin-Induced Dementia Model: Neuroprotection with Aminoguanidine. *Adv. Alzheimer's Dis.* **2011**, *1*, 215–227. [[CrossRef](#)]
90. Tramontina, A.C.; Wartchow, K.M.; Rodrigues, L.; Biasibetti, R.; Quincozes-Santos, A.; Bobermin, L.; Tramontina, F.; Gonçalves, C.-A. The Neuroprotective Effect of Two Statins: Simvastatin and Pravastatin on a Streptozotocin-Induced Model of Alzheimer's Disease in Rats. *J. Neural Transm.* **2011**, *118*, 1641–1649. [[CrossRef](#)] [[PubMed](#)]

Disclaimer/Publisher's Note: The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content.